Neurocrine biosciences presents new positive data from phase 2 study of nbi-1117568 in adults with schizophrenia at american society of clinical psychopharmacology 2025

San diego , may 28, 2025 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today announced the presentation of data from the phase 2 study of nbi-1117568 in adults with schizophrenia, which showed a significant improvement in symptoms and overall severity and highlighted new data on the safety and tolerability of the treatment. nbi-1117568 is the first and only investigational oral muscarinic m4 selective orthosteric agonist in clinical development as a potential treatment for schizophrenia.
NBIX Ratings Summary
NBIX Quant Ranking